AG404® - Clinical Research Data Summary

Ag404® Nanoscale Silver Technology

Ag404® is a clinically studied ingredient used in the following Silver Fern™ Brand products:

Introduction

Ag404® is a nanoscale silver technology composed of ultra-small silver particles dispersed in purified water. This form of engineered silver has been studied in several scientific contexts to better understand its interaction with biological systems. Human clinical studies evaluating orally administered nanosilver solutions derived from this technology platform have examined systemic safety markers including metabolic panels, hematologic measures, platelet activity, inflammatory markers, organ imaging, and drug-metabolizing enzyme activity. Across these controlled studies, researchers reported that short-term exposure to nanosilver solutions produced measurable circulating silver levels but did not result in clinically meaningful changes in the physiological markers evaluated under the conditions studied.

In addition to controlled human investigations, observational clinical documentation and preclinical research provide additional scientific context regarding nanosilver interactions with microorganisms and biological systems. Observational clinical reports from hospital settings have described physician observations following nanosilver use in real-world clinical environments, although these reports were not randomized controlled trials and therefore cannot establish cause-and-effect outcomes. Laboratory and experimental studies have also evaluated nanosilver materials in antimicrobial and parasitology research models. These studies have examined interactions between nanosilver particles and microbial organisms, biofilms, protozoan parasites, and model organisms commonly used in biological research. Together, these findings contribute to the broader scientific literature exploring how nanosilver materials behave in microbial environments and biological systems.

These are the studies for Ag404®. Below, we provided a summary of each key data for each study, along with a link to the complete human clinical research.

  1. Summary of Study 1 – Full Study: https://pubmed.ncbi.nlm.nih.gov/23811290/
  2. Summary of Study 2 – Full Study: https://pubmed.ncbi.nlm.nih.gov/23517080/
  3. Summary of Study 3 – Full Study: https://pubmed.ncbi.nlm.nih.gov/25137296/
  4. Additional Research: Observational Clinical Report
  5. Antimicrobial and Anti-Biofilm Gel Study
  6. Preclinical Parasite Research: Cryptosporidium parvum Model
  7. Preclinical Parasite Study: Leishmania (U.S. Army Research)
  8. Preclinical Parasite Model Study: Caenorhabditis elegans (Nematode Model)

Ingredient Manufacturer Link: https://ablmfg.com/



Study 1 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/23811290/

In Vivo Human Time-Exposure Study of Orally Dosed Commercial Silver Nanoparticles
Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28. PMID: 23811290; PMCID: PMC3877176.

This human clinical safety study evaluated the biodistribution and potential toxicity of orally consumed nanoscale silver particle solutions in healthy adults. In a prospective, single-blind, controlled, crossover design, sixty participants consumed commercially available nanosilver solutions at concentrations of 10 ppm and 32 ppm. Researchers monitored multiple biological systems including metabolic markers, hematology, urinalysis, inflammatory markers, and organ morphology using magnetic resonance imaging of the chest and abdomen. Silver levels were also measured in blood and urine to assess absorption and elimination. Across all monitored parameters, investigators reported no clinically meaningful changes in metabolic, hematologic, urinary, inflammatory, or imaging outcomes following oral exposure to nanosilver solutions under the study conditions.

Study Design Highlights

  • Study design: Prospective, single-blind, controlled crossover human study
  • Participants: 60 healthy adult volunteers
  • Dosing: Oral ingestion of commercially available nanosilver particle solutions at concentrations of:
    • 10 ppm
    • 32 ppm
  • Duration: Participants were evaluated before and after exposure during the crossover study period while undergoing metabolic testing, laboratory analysis, and imaging assessments
  • Measured outcomes: Researchers evaluated multiple safety markers including:
    • Metabolic markers: blood chemistry panels
    • Hematologic markers: complete blood counts
    • Renal markers: urinalysis and urinary silver concentrations
    • Respiratory markers: sputum induction to evaluate pulmonary responses
    • Inflammatory markers: pulmonary reactive oxygen species and pro-inflammatory cytokines
    • Organ morphology: magnetic resonance imaging of lungs, heart, and abdominal organs
    • Biodistribution: silver concentrations measured in serum and urine

Key Findings (What the Study Showed)

No Clinically Meaningful Changes Across Monitored Systems

No clinically meaningful changes were observed across the monitored biological systems. Investigators reported:

  • No statistically significant change in metabolic laboratory markers
  • No statistically significant change in hematologic markers
  • No statistically significant change in urinalysis measures
  • No observable morphological change in the lungs, heart, or abdominal organs on MRI
  • No significant increases in inflammatory cytokines or pulmonary oxidative stress markers

Conclusion

Under the conditions tested, oral exposure to nanoscale silver particle solutions at 10 ppm and 32 ppm did not produce clinically significant changes in metabolic, hematologic, urinary, inflammatory, or imaging findings in healthy adults. The authors noted that further research examining longer exposure periods and additional organ systems would help define safety thresholds for nanosilver use.

Practical Real-World Relevance of This Study

Based directly on the study design and findings, this research provides:
✓ Controlled human data evaluating systemic safety markers following oral exposure to nanosilver solutions
✓ Multi-system safety monitoring across metabolic, cardiovascular, pulmonary, and renal parameters simultaneously
✓ Absorption and elimination insight via measurement of serum and urinary silver levels
✓ Support for safety assessments given the absence of clinically significant changes in laboratory values or imaging findings
✓ A foundation for future research investigating longer exposure periods, dosing ranges, and additional physiological systems

Why This Study Matters

This study provides controlled human data evaluating systemic safety markers following oral exposure to nanosilver solutions. Researchers assessed several organ systems simultaneously, including metabolic, cardiovascular, pulmonary, and renal parameters. Measurement of serum and urinary silver levels provided information about how nanosilver is processed and cleared by the body. The absence of clinically significant changes in laboratory values or imaging findings may contribute to broader toxicological and safety evaluations of nanosilver materials used in consumer or healthcare products, and the findings help guide future studies investigating longer exposure periods, dosing ranges, and additional physiological systems.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/23811290/



Study 2 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/23517080/

Assessment of Orally Dosed Commercial Silver Nanoparticles on Human Ex Vivo Platelet Aggregation
Nanotoxicology. 2014 May;8(3):328-33. doi: 10.3109/17435390.2013.788749. Epub 2013 May 2. PMID: 23517080.

This human clinical study evaluated whether oral exposure to silver nanoparticle solutions affects platelet aggregation, an important factor related to blood clotting and cardiovascular health. Because previous laboratory studies suggested that direct exposure of platelets to silver nanoparticles could increase aggregation, researchers designed a placebo-controlled, single-blind crossover study in healthy adults to determine whether the same effect occurs following oral ingestion. Eighteen volunteers consumed a silver nanoparticle solution daily for two weeks, after which platelet aggregation was measured using standard light transmission aggregometry following stimulation with collagen and ADP. Results showed that oral exposure resulting in peak serum silver levels below 10 µg/L did not produce detectable increases in platelet activation or aggregation compared with placebo.

Study Design Highlights

  • Study design: Placebo-controlled, single-blind, dose-monitored crossover human study
  • Participants: 18 healthy adult volunteers
  • Dosing: Participants ingested a nanosilver particle solution orally once daily for 2 weeks
  • Duration: Daily exposure for 14 days before platelet function testing
  • Measured outcomes: Researchers evaluated platelet aggregation using light transmission aggregometry following stimulation with two common platelet agonists:
    • Collagen
    • ADP (adenosine diphosphate)
  • Platelet aggregation was measured at baseline and after exposure to nanosilver or placebo
  • Researchers also monitored circulating silver concentrations in serum to assess systemic exposure

Key Findings (What the Study Showed)

No Increase in Platelet Aggregation or Activation

Following two weeks of oral nanosilver exposure:

  • Peak serum silver concentrations remained below 10 µg/L
  • No enhanced platelet activation was detected
  • No increase in platelet aggregation compared with placebo
  • Platelet responses to collagen and ADP remained within normal physiological ranges
  • 0% increase in platelet aggregation compared with placebo
  • 0% clinically significant change in platelet activation markers

Conclusion

Under the study conditions, two weeks of daily oral nanosilver ingestion did not increase platelet aggregation or platelet activation in healthy adults. The authors concluded that further research may be useful to evaluate additional exposure durations and concentrations to better characterize potential platelet-related effects.

Practical Real-World Relevance of This Study

Based directly on the study design and findings, this research provides:
✓ A direct evaluation of whether nanosilver exposure influences platelet behavior, relevant to cardiovascular risk assessments
✓ Controlled human data rather than relying only on laboratory or animal findings
✓ Translation of laboratory findings to humans — although previous in vitro experiments suggested silver nanoparticles could increase platelet aggregation, this study indicates that oral exposure at tested levels did not produce the same effect
✓ Exposure context by measuring serum silver concentrations during the trial, clarifying biological exposure levels associated with typical oral nanosilver use
✓ Contribution to safety evaluations of nanosilver-containing materials when assessing potential effects on blood clotting mechanisms

Why This Study Matters

This study directly evaluated whether nanosilver exposure influences platelet behavior, which is relevant to cardiovascular risk assessments. The research provides controlled human data rather than relying only on laboratory or animal findings. Although previous in vitro experiments suggested silver nanoparticles could increase platelet aggregation, this study indicates that oral exposure at tested levels did not produce the same effect in humans. By measuring serum silver concentrations during the trial, the study helps clarify the biological exposure levels associated with typical oral nanosilver use, and these findings may help inform safety evaluations of nanosilver-containing materials and products when assessing potential effects on blood clotting mechanisms.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/23517080/



Study 3 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/25137296/

Assessing Orally Bioavailable Commercial Silver Nanoparticle Product on Human Cytochrome P450 Enzyme Activity
Nanotoxicology. 2015 May;9(4):474-81. doi: 10.3109/17435390.2014.948092. Epub 2014 Aug 19. PMID: 25137296.

This human clinical study investigated whether oral ingestion of a nanosilver product affects the activity of cytochrome P450 enzymes, which play a central role in the metabolism of many medications. Because nanoparticles can accumulate in the liver and potentially influence metabolic pathways, researchers designed a prospective, single-blind, controlled in vivo study to evaluate whether nanosilver exposure alters the activity of key drug-metabolizing enzymes. Healthy volunteers consumed a commercially available nanosilver solution for 14 days while researchers monitored the activity of several major cytochrome P450 enzymes using standardized probe compounds. Although measurable levels of silver were detected in serum after the dosing period, investigators reported no clinically significant changes in metabolic markers, hematologic parameters, urinary findings, physical assessments, or cytochrome P450 enzyme activity compared with baseline.

Study Design Highlights

  • Study design: Prospective, single-blind, controlled in vivo human study
  • Participants: Healthy adult volunteers
  • Dosing: Participants orally ingested a commercially available nanosilver solution daily
  • Duration: 14 days of continuous oral exposure
  • Measured outcomes: Researchers evaluated the potential interaction of nanosilver with major drug-metabolizing enzymes by administering standardized probe compounds for five cytochrome P450 enzyme classes:
    • CYP1A2
    • CYP2C9
    • CYP2C19
    • CYP2D6
    • CYP3A4
  • In addition to enzyme activity, investigators monitored several clinical safety parameters:
    • Metabolic markers: blood chemistry and metabolic panels
    • Hematologic markers: complete blood counts
    • Renal markers: urinalysis
    • Physical assessments: general clinical examination and safety observations
    • Biodistribution: serum silver concentrations measured to confirm systemic exposure

Key Findings (What the Study Showed)

No Clinically Significant Changes in Enzyme Activity or Safety Markers

After 14 days of oral nanosilver ingestion:

  • Detectable silver levels were present in human serum
  • No clinically significant changes were observed in metabolic laboratory markers
  • No clinically significant changes were observed in hematologic markers
  • No clinically significant changes were observed in urinalysis results
  • No measurable inhibition or induction of cytochrome P450 enzymes was detected
  • 0% clinically significant change in cytochrome P450 enzyme activity
  • 0% clinically significant change in metabolic laboratory markers
  • 0% clinically significant change in hematologic or urinary parameters

Conclusion

Under the conditions of this study, oral ingestion of a nanosilver solution for 14 days resulted in measurable systemic exposure but did not produce clinically significant changes in cytochrome P450 enzyme activity or other monitored clinical safety markers. The authors noted that additional research may further characterize potential interactions between nanosilver and metabolic pathways across longer exposure periods or with other nanotechnology-based materials.

Practical Real-World Relevance of This Study

Based directly on the study design and findings, this research provides:
✓ Evaluation of whether nanosilver exposure alters cytochrome P450 metabolic pathways, which are responsible for metabolizing many medications
✓ Human exposure assessment confirming that orally ingested nanosilver can be detected in serum
✓ Evaluation of potential drug interactions — the absence of measurable enzyme inhibition or induction suggests nanosilver exposure under tested conditions did not alter the metabolic pathways evaluated
✓ Support for safety characterization through human clinical monitoring of multiple physiological systems
✓ A foundation for further research into nanoparticle exposure and potential interactions with biological metabolic systems

Why This Study Matters

Cytochrome P450 enzymes are responsible for metabolizing many medications. This study evaluated whether nanosilver exposure alters these metabolic pathways, and the research confirmed that orally ingested nanosilver can be detected in serum, providing information about systemic absorption. The absence of measurable enzyme inhibition or induction suggests that nanosilver exposure under the tested conditions did not alter the metabolic pathways evaluated in the study. Human clinical monitoring of multiple physiological systems provides additional data that can contribute to broader toxicological and safety evaluations of nanosilver-containing products, and the findings help guide future investigations into nanoparticle exposure and potential interactions with biological metabolic systems.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/25137296/



Observational Clinical Report

Complete Study Information: https://ablmfg.com/

Clinical Observations of Nanosilver Solution Use in Ghana Medical Facilities
American Biotech Labs clinical report, Ghana observational case series.

An observational clinical report from healthcare settings in Ghana evaluated the use of nanosilver solutions in patients presenting with a variety of infectious conditions. The report compiled outcomes from patients treated in clinical environments using a nanosilver preparation similar to the technology platform used in Ag404®. Physicians documented patient presentations, dosing approaches, and reported symptom resolution timelines. Because this report represents observational clinical data rather than a randomized controlled trial, it provides descriptive insight into real-world clinical use rather than establishing cause-and-effect therapeutic outcomes.

Study Design Highlights

  • Study type: Observational clinical report (case-series style documentation)
  • Setting: Clinical and hospital settings in Ghana
  • Participants: Approximately 50+ patients treated by physicians using nanosilver preparations
  • Conditions reported in the observational report included:
    • Malaria
    • Bronchitis
    • Sinus infections
    • Skin infections
    • Urinary tract infections
    • Gastrointestinal infections
    • Pharyngitis
  • Treatment approach: Patients received nanosilver solutions administered by clinicians according to the treatment protocol used in those clinical settings

Key Observations

Reported Physician Observations

Physicians reported that many patients experienced improvement in symptoms within several days following treatment. Examples described in the report included:

  • Gastrointestinal symptoms resolving within approximately 1 day
  • Sinus infection symptoms improving within approximately 3 days
  • Malaria-related symptom observations reported within approximately 4 days in some cases

Important Study Limitation

This report represents observational clinical documentation rather than a randomized controlled trial. As a result, it does not establish causation and should be interpreted as descriptive real-world clinical experience rather than proof of efficacy.

Real-World Relevance

Observational clinical reports can provide insight into how healthcare practitioners use certain materials or technologies in clinical environments. While controlled trials are required to determine clinical efficacy, case-series style reports help generate hypotheses for future research and highlight areas where additional controlled studies may be warranted. In this case, the report documents physician observations following nanosilver use in a variety of clinical scenarios, contributing to the broader body of research exploring nanosilver materials.

Reference Link: American Biotech Labs. Clinical observations of nanosilver solution use in Ghana hospital settings. Observational clinical report. https://ablmfg.com/



Antimicrobial and Anti-Biofilm Gel Study

Complete Study Information: https://www.hmpgloballearningnetwork.com/site/wounds

Novel Silver-Based Platform Technology: Antimicrobial and Antibiofilm Activity of Nanosilver Gel Formulations
American Biotech Labs. Scientific poster presented at the Symposium on Advanced Wound Care (SAWC) Spring Conference, 2023.

This laboratory study evaluated the antimicrobial and anti-biofilm activity of nanosilver gel formulations against a range of clinically relevant bacterial and fungal pathogens. Researchers tested the ability of nanosilver-containing gels to inhibit microbial growth and disrupt biofilm formation under controlled laboratory conditions. Biofilms are structured communities of microorganisms that can adhere to surfaces and are often associated with increased microbial persistence. The study examined the activity of nanosilver formulations against multiple organisms commonly used in antimicrobial testing models.

Study Design Highlights

  • Study type: Laboratory antimicrobial and antibiofilm study
  • Experimental setting: Controlled microbiology laboratory testing
  • Pathogens evaluated:
    • Bacteria:
      • Methicillin-resistant Staphylococcus aureus (MRSA)
      • Pseudomonas aeruginosa
      • Escherichia coli O157
      • Enterobacter cloacae
      • Enterococcus faecalis
      • Klebsiella pneumoniae
      • Acinetobacter baumannii
    • Fungi:
      • Candida albicans
      • Candida auris
      • Aspergillus flavus
  • Measured outcomes:
    • Inhibition of microbial growth
    • Antimicrobial activity against tested organisms
    • Ability to disrupt established biofilms

Key Observations

Nanosilver gel formulations demonstrated antimicrobial activity against the tested bacterial and fungal organisms under laboratory conditions. The formulations also inhibited biofilm formation in experimental models of MRSA and Pseudomonas aeruginosa biofilms.

Conclusion

In controlled laboratory experiments, nanosilver gel formulations demonstrated antimicrobial activity and biofilm disruption against several bacterial and fungal organisms commonly used in antimicrobial research models. These findings provide experimental evidence of nanosilver's interaction with microbial systems in laboratory settings and contribute to the broader scientific investigation of nanosilver materials.

Real-World Relevance

Laboratory antimicrobial studies help researchers understand how materials interact with microorganisms in controlled conditions. Biofilm formation is an important area of microbiology research because biofilms can contribute to microbial persistence on surfaces and biological tissues. By evaluating antimicrobial activity and biofilm interactions, studies such as this help inform ongoing research into how nanosilver materials behave in microbial environments.

Reference Link: Scientific poster presented at the Symposium on Advanced Wound Care (SAWC) Spring Conference, 2023. https://www.hmpgloballearningnetwork.com/site/wounds



Preclinical Parasite Research: Cryptosporidium parvum Model

Complete Study Information: Reduction of Cryptosporidium parvum infectivity following nanosilver exposure in experimental models. Parasitology laboratory study.

This experimental study evaluated the effects of nanosilver particles on the protozoan parasite Cryptosporidium parvum, an organism commonly used in parasitology research due to its role in gastrointestinal infections. Researchers investigated whether nanosilver exposure influenced parasite infectivity and survival in controlled laboratory models. Cryptosporidium parvum is frequently studied in experimental settings because of its environmental resilience and relevance to waterborne parasitic disease research.

Study Design Highlights

  • Study type: Experimental parasitology study (preclinical laboratory research)
  • Organism studied: Cryptosporidium parvum
  • Experimental setting: Controlled laboratory and parasite infectivity models
  • Study objective: To evaluate whether nanosilver particles influence the viability and infectivity of Cryptosporidium parasites under experimental conditions
  • Measured outcomes:
    • Parasite survival following nanosilver exposure
    • Parasite infectivity in experimental models
    • Changes in parasite activity following treatment conditions

Key Observations

Exposure to nanosilver particles reduced parasite infectivity and viability in laboratory models under the conditions tested.

Conclusion

Under controlled experimental conditions, nanosilver exposure influenced Cryptosporidium parvum infectivity in laboratory models. These findings contribute to the broader scientific investigation of nanosilver interactions with parasitic organisms in experimental research environments.

Real-World Relevance

Experimental parasitology studies help researchers evaluate how emerging materials interact with microorganisms and parasites under controlled conditions. Cryptosporidium is commonly used in research models because it is environmentally resilient and relevant to gastrointestinal infection studies. Laboratory findings such as these provide insight into how nanosilver particles interact with biological organisms and help guide further investigation into the behavior of nanosilver materials in microbial environments.



Preclinical Parasite Study: Leishmania (U.S. Army Research)

Complete Study Information: Experimental evaluation of nanosilver activity against Leishmania parasites. Military medical parasitology study.

This experimental study evaluated the effects of nanosilver particles on the parasite Leishmania, an organism responsible for leishmaniasis and commonly used in parasitology research models. The research, conducted by military medical investigators, examined whether nanosilver exposure influenced parasite growth under controlled laboratory conditions. Laboratory models using Leishmania parasites are frequently used to study interactions between antimicrobial agents and protozoan pathogens.

Study Design Highlights

  • Study type: Experimental parasitology study (preclinical laboratory research)
  • Organism studied: Leishmania parasite (promastigote stage)
  • Experimental setting: Controlled laboratory conditions
  • Study objective: To evaluate whether nanosilver particles influence the growth and viability of Leishmania parasites in vitro
  • Measured outcomes:
    • Parasite growth rate following nanosilver exposure
    • Parasite viability under experimental conditions
    • Inhibitory effects on parasite proliferation

Key Observations

Nanosilver exposure inhibited growth of Leishmania promastigotes under laboratory conditions, suggesting interaction between nanosilver particles and the parasite model used in the study.

Conclusion

In laboratory experiments, nanosilver particles influenced the growth behavior of Leishmania parasites in vitro. These findings contribute to experimental research exploring how nanosilver materials interact with parasitic organisms in controlled environments.

Real-World Relevance

Laboratory parasite models such as Leishmania are widely used in biomedical research to investigate how new materials interact with protozoan pathogens. Experimental studies like this help researchers understand how nanosilver particles behave in microbial environments and provide preliminary data that can inform future investigations.



Preclinical Parasite Model Study: Caenorhabditis elegans (Nematode Model)

Complete Study Information: Evaluation of nanosilver exposure effects in the Caenorhabditis elegans nematode model. Experimental organism study.

This experimental study evaluated the interaction between nanosilver particles and the nematode Caenorhabditis elegans, a model organism frequently used in toxicology, microbiology, and parasitology research. The C. elegans model is widely used in biomedical science because its biological pathways share similarities with many higher organisms, allowing researchers to study how compounds interact with living systems under controlled conditions.

Study Design Highlights

  • Study type: Experimental model organism study (preclinical research)
  • Organism studied: Caenorhabditis elegans (nematode model organism)
  • Experimental setting: Controlled laboratory model system
  • Study objective: To evaluate how nanosilver exposure influences nematode viability and biological responses in a model organism system
  • Measured outcomes:
    • Nematode survival following nanosilver exposure
    • Biological response of the organism to nanosilver particles
    • Dose-dependent effects on organism viability

Key Observations

Nanosilver exposure affected nematode survival and biological responses in the C. elegans model under the experimental conditions studied.

Conclusion

In controlled laboratory experiments, nanosilver particles influenced biological responses in the Caenorhabditis elegans model organism. These findings contribute to experimental research investigating interactions between nanosilver materials and living biological systems.

Real-World Relevance

Model organisms such as C. elegans are widely used in biomedical research to explore biological interactions of new materials before human studies are conducted. These models allow researchers to observe organism-level responses in a controlled environment and provide early insights into how substances interact with living systems.

Big-Picture Integration with Other Studies

  • Study 1: In a single-blind crossover study of 60 healthy adults, oral ingestion of 10 ppm and 32 ppm nanosilver solutions showed no clinically meaningful changes in metabolic, hematologic, inflammatory, or imaging markers of health.
  • Study 2: In a placebo-controlled crossover study of 18 healthy adults, two weeks of oral nanosilver ingestion did not increase platelet aggregation or activation compared with placebo.
  • Study 3: In a controlled human study, 14 days of oral nanosilver ingestion produced detectable serum silver levels but did not alter cytochrome P450 enzyme activity or clinical laboratory markers related to drug metabolism.
  • Observational Clinical Report: An observational clinical report from hospital settings in Ghana described patient outcomes following use of nanosilver preparations across several infectious conditions, with reported symptom resolution occurring within several days in many cases.
  • Antimicrobial and Anti-Biofilm Gel Study: A laboratory antimicrobial study evaluated nanosilver gel formulations against multiple bacterial and fungal pathogens and observed inhibition of microbial growth and disruption of biofilm formation under experimental conditions.
  • Preclinical Parasite Research: Cryptosporidium parvum Model: An experimental parasitology study evaluated nanosilver exposure against Cryptosporidium parvum and observed reductions in parasite infectivity in laboratory models.
  • Preclinical Parasite Study: Leishmania (U.S. Army Research): An experimental parasitology study conducted by military medical researchers evaluated nanosilver exposure against Leishmania parasites and observed inhibition of parasite growth in laboratory conditions.
  • Preclinical Parasite Model Study: Caenorhabditis elegans (Nematode Model): A model organism study evaluated nanosilver exposure in the Caenorhabditis elegans nematode system and observed effects on organism viability under experimental conditions.

Ag404® Ingredient Summary & Real-World Relevance

The available body of research surrounding Ag404® nanosilver technology includes human clinical safety studies, observational clinical reports, and laboratory research investigating microbial and biological interactions. Controlled human studies have evaluated systemic safety markers following nanosilver ingestion and reported no clinically meaningful changes in metabolic, hematologic, inflammatory, or imaging outcomes under the conditions studied. Additional laboratory investigations have explored nanosilver interactions with microbial organisms and experimental parasite models, while observational reports have documented real-world clinical use in certain healthcare environments. Because many of these studies represent experimental or observational research rather than randomized therapeutic trials, their findings are best interpreted as contributing to the scientific understanding of nanosilver materials rather than establishing medical outcomes.

From a practical perspective, this research helps inform ongoing scientific evaluation of nanosilver technologies and their biological interactions. Studies examining biodistribution, metabolic markers, microbial models, and biological systems provide researchers with insight into how nanosilver particles behave under controlled laboratory and clinical conditions. As research in nanotechnology continues to evolve, these findings contribute to the broader effort to characterize the safety, biological behavior, and potential applications of engineered nanosilver materials in consumer, hygiene, and healthcare-related technologies.

Ingredient Manufacturer Link: https://ablmfg.com/

Ag404® is a clinically studied ingredient used in the following Silver Fern™ Brand products:

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Go to full site